FDA approves ADHD drug to treat binge-eating
The U.S. and Food and Drug Administration (FDA) has, for the first time, approved a drug to treat binge-eating–a disorder characterized by repeated episodes of uncontrolled eating.
The drug is Vyvanse, a stimulant often prescribed as a treatment for ADHD.
Scientists tested Vyvanse on patients in various clinical studies and compared the effects with those from a placebo. At the start of the study, the patients on average reported bingeing on 4.79 days per week. After 12 weeks, the patients who received the drug on average reported bingeing on fewer than one day per week. The patients who received a placebo saw less of a reduction in their weekly binge days.
Researchers anticipate the drug could help many of the roughly 2.8 million people in the U.S. who currently live with binge-eating disorder. They did warn against the drug’s potential side effects, which may include elevated blood pressure and heart rate, insomnia, hallucinations and risk for abuse and addiction.